Get the Stockscreener App
85.88
0.93%
-0.683
Incyte Corp stock is traded at $85.88, with a volume of 1.01M.
It is down -0.93% in the last 24 hours and up +9.39% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
See More
Previous Close:
$86.56
Open:
$86.39
24h Volume:
1.01M
Relative Volume:
0.58
Market Cap:
$16.72B
Revenue:
$4.58B
Net Income/Loss:
$870.87M
P/E Ratio:
19.52
EPS:
4.4
Net Cash Flow:
$945.58M
1W Performance:
-0.26%
1M Performance:
+9.39%
6M Performance:
+21.14%
1Y Performance:
+37.73%
1-Day Range:
$85.51
$87.35
1-Week Range:
$85.06
$87.99
52-Week Range:
$53.56
$87.99
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
85.62 | 16.90B | 4.58B | 870.87M | 945.58M | 4.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.76 | 101.34B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
482.64 | 59.64B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.32 | 59.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
766.51 | 47.00B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
349.87 | 38.12B | 3.81B | -644.79M | -669.77M | -6.24 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Incyte (INCY) Rating Affirmed with Increased Price Target by B o - GuruFocus
Can trapped investors hope for a rebound in Incyte CorporationTrade Ideas & Technical Pattern Based Signals - Newser
Is Incyte Corporation forming a bullish divergence2025 Momentum Check & Capital Protection Trade Alerts - خودرو بانک
Incyte’s Pipeline And Profits Shine Despite Patent Uncertainty - Finimize
Does Incyte Corporation stock benefit from AI growthTrade Ideas & Weekly High Potential Stock Alerts - خودرو بانک
Will Incyte Corporation outperform the market2025 Price Targets & Weekly Stock Breakout Alerts - Newser
Technical signs of recovery in Incyte Corporation2025 Trade Ideas & Verified Short-Term Plans - Newser
Using economic indicators to assess Incyte Corporation potentialQuarterly Earnings Summary & Low Risk Entry Point Guides - Newser
Is Incyte Corporation stock reversal real or fake2025 Winners & Losers & Long-Term Growth Plans - Newser
Is Incyte Corporation showing insider buyingDividend Hike & Consistent Income Trade Recommendations - خودرو بانک
Incyte Corp EVP Sheila Denton Buys, Sells Shares on 2025-09-02 - AInvest
Incyte at Wells Fargo Conference: Strategic Growth Plans - Investing.com
What indicators show strength in Incyte CorporationJuly 2025 Technicals & Daily Entry Point Alerts - Newser
Using portfolio simulators with Incyte Corporation includedMarket Activity Recap & Long-Term Growth Portfolio Plans - Newser
Myelofibrosis Market is Going to Grow at a CAGR of 9% in the Next Ten Years (2025-2034) | DelveInsight - sg.finance.yahoo.com
How to build a custom watchlist for Incyte CorporationLong Setup & Expert Approved Momentum Trade Ideas - Newser
Combining price and volume data for Incyte CorporationRecession Risk & Accurate Buy Signal Notifications - Newser
Incyte at Cantor Global Healthcare Conference: Strategic Growth Beyond 2029 - Investing.com
Incyte launches educational campaign to raise awareness of HS - Investing.com
Incyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa - Financial Times
Should you wait for a breakout in Incyte CorporationShare Buyback & Scalable Portfolio Growth Ideas - Newser
Should I invest in Incyte Corporation before earnings2025 Historical Comparison & High Return Stock Watch Alerts - خودرو بانک
Quantitative breakdown of Incyte Corporation recent moveTreasury Yields & Daily Chart Pattern Signal Reports - Newser
What candlestick patterns are forming on Incyte CorporationWeekly Trend Recap & Step-by-Step Swing Trade Plans - Newser
What Fibonacci levels say about Incyte Corporation rebound2025 Big Picture & Long-Term Growth Stock Strategies - Newser
Will breakout in Incyte Corporation lead to full recoveryCPI Data & Proven Capital Preservation Methods - Newser
Cholangiocarcinoma Market Outlook 2034 – Clinical Trials, Market Size, Medication, Prevalence, Companies by DelveInsight - Barchart.com
Incyte (INCY) Stock Is Up, What You Need To Know - Yahoo Finance
Advanced analytics toolkit walkthrough for Incyte CorporationJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
Applying Elliott Wave Theory to Incyte CorporationAnalyst Upgrade & Smart Allocation Stock Tips - Newser
Incyte Corporation stock hits 52-week high at 87.27 USD - Investing.com
What’s the recovery path for long term holders of Incyte CorporationJuly 2025 Opening Moves & Technical Pattern Alert System - Newser
Reversal indicators forming on Incyte Corporation stockWeekly Market Outlook & Intraday High Probability Setup Alerts - Newser
Can Incyte Corporation disrupt its industry2025 Short Interest & Safe Capital Growth Tips - khodrobank.com
What institutional flow reveals about Incyte CorporationJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
How sentiment analysis helps forecast Incyte CorporationBull Run & Fast Exit/Entry Strategy Plans - Newser
Long term hold vs stop loss in Incyte CorporationJuly 2025 Catalysts & Weekly Setup with ROI Potential - Newser
Will Incyte Corporation stock recover after recent dropDividend Hike & Growth Oriented Trading Recommendations - Newser
Did Incyte's (INCY) Leadership Shift and Pipeline Milestones Just Reshape Its Investment Narrative? - Yahoo Finance
Can technical indicators confirm Incyte Corporation’s reversalPortfolio Risk Summary & Expert Curated Trade Setup Alerts - Newser
How institutional ownership impacts Incyte Corporation stockJuly 2025 Chart Watch & Advanced Technical Analysis Signals - Newser
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Incyte Corp Stock (INCY) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Denton Sheila A. | EVP & General Counsel |
Sep 02 '25 |
Sale |
84.97 |
598 |
50,812 |
33,200 |
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):